QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touchService navigator
QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touch

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

Why choose us?

Customer satisfaction is our absolute priority

Your timeline is our timeline

f

Every study is custom-built

p

Scientific input to study design and data interpretation

Extensive experience with virtually all drug targets and treatment types

0

Wide range of validated models and techniques for comprehensive compound tests from a single source

AAALAC certification ensures highest quality standards

QPS Austria AAALAC accrediation Logo

QPS NEURO NEWS

QPS NEURO and PRONEXUS Analytical AB announcing joint partnership

Announcement NEWS

QPS NEURO & PRONEXUS ANALYTICAL

February 6, 2018, Graz (Austria), Stockholm (Sweden) – QPS Neuro and Pronexus announced formation of a joint partnership aiming to build their respective areas of expertise on unified experimental platforms and offer a broader suite of services to their clients.

The effects of test compounds can be now evaluated from in vitro screening tests in cell cultures to in vivo studies in rodent models of psychiatric, neurodegenerative, rare disease and metabolic disorders and implementing molecular, immunohistochemical, neurochemical and behavioral techniques.

QPS Neuro is the Austria based early development site of QPS Holdings, LLC, a leading full-service contract research organization and has developed its reputation over the past three decades as a specialist in CNS and Orphan diseases including Alzheimer’s and Parkinson’s disease as well as HD, NPC, ALS, depression, psychosis and schizophrenia. QPS is a leading provider of genetically modified organisms for research in CNS diseases and able to combine behavioral analysis, neurochemistry and biochemistry as well as quantitative histology and histopathology. In addition, QPS Neuro has experience and access to unique biomarker technologies, owning, for example, the worldwide exclusive license to the A4-assay for A-beta oligomers from ProMIS Neurosciences.

We are all excited about this partnership with Pronexus Analytical, because it offers synergies for both partners. Our broad range of experience and the unique knowledge about our animal models, combined with the specific services available from Pronexus will help our clients to expedite new drug developments. Our future collaboration will afford market competitiveness, and allow us to remain the CNS specialist in early drug development” says Dr. Ben Chien, GM of QPS Austria GmbH and CEO of QPS Holdings, LLC.

Pronexus Analytical is a preclinical CRO offering advanced services in CNS pharmacology, neurochemistry and bioanalysis. Pronexus core expertise is focused on PK/PD studies using in vivo microdialysis, CSF, blood microsampling and brain microdissections. The bioanalytical services include UHPLC-MS/MS, UPLC-TOF, high-sensitive HPLC methods, and immunoassays for measuring the levels of neurotransmitters and other signaling molecules, metabolites, as well as concentrations of drugs and toxins in biological samples including microdialysates, cell lysates, CSF, plasma, urine and tissue extracts. http://www.pronexus.se/

I am delighted to be working with QPS Holdings, incorporating their renowned expertise in disease models”, said Dr. Jan Kehr, CEO of Pronexus Analytical AB, Sweden. “I believe the addition of Pronexus capabilities to monitor brain chemistry together with the QPS portfolio of behavioral tests and immunohistochemical assays will allow us to help our clients to better understand drug actions at a more detailed and quantitative level, and thereby improve predictability of efficacy and therapeutic utility of drug candidates in clinical trials”.

QPS NEURO and PRONEXUS Analytical AB announcing joint partnership

Announcement NEWS

QPS NEURO & PRONEXUS ANALYTICAL

February 6, 2018, Graz (Austria), Stockholm (Sweden). QPS Neuro and Pronexus announced formation of a joint partnership aiming to build their respective areas of expertise on unified experimental platforms and offer a broader suite of services to their clients.

The effects of test compounds can be now evaluated from in vitro screening tests in cell cultures to in vivo studies in rodent models of psychiatric, neurodegenerative, rare disease and metabolic disorders and implementing molecular, immunohistochemical, neurochemical and behavioral techniques.

QPS Neuro is the Austria based early development site of QPS Holdings, LLC, a leading full-service contract research organization and has developed its reputation over the past three decades as a specialist in CNS and Orphan diseases including Alzheimer’s and Parkinson’s disease as well as HD, NPC, ALS, depression, psychosis and schizophrenia. QPS is a leading provider of genetically modified organisms for research in CNS diseases and able to combine behavioral analysis, neurochemistry and biochemistry as well as quantitative histology and histopathology. In addition, QPS Neuro has experience and access to unique biomarker technologies, owning, for example, the worldwide exclusive license to the A4-assay for A-beta oligomers from ProMIS Neurosciences.

We are all excited about this partnership with Pronexus Analytical, because it offers synergies for both partners. Our broad range of experience and the unique knowledge about our animal models, combined with the specific services available from Pronexus will help our clients to expedite new drug developments. Our future collaboration will afford market competitiveness, and allow us to remain the CNS specialist in early drug development” says Dr. Ben Chien, GM of QPS Austria GmbH and CEO of QPS Holdings, LLC.

Pronexus Analytical is a preclinical CRO offering advanced services in CNS pharmacology, neurochemistry and bioanalysis. Pronexus core expertise is focused on PK/PD studies using in vivo microdialysis, CSF, blood microsampling and brain microdissections. The bioanalytical services include UHPLC-MS/MS, UPLC-TOF, high-sensitive HPLC methods, and immunoassays for measuring the levels of neurotransmitters and other signaling molecules, metabolites, as well as concentrations of drugs and toxins in biological samples including microdialysates, cell lysates, CSF, plasma, urine and tissue extracts. http://www.pronexus.se/

I am delighted to be working with QPS Holdings, incorporating their renowned expertise in disease models”, said Dr. Jan Kehr, CEO of Pronexus Analytical AB, Sweden. “I believe the addition of Pronexus capabilities to monitor brain chemistry together with the QPS portfolio of behavioral tests and immunohistochemical assays will allow us to help our clients to better understand drug actions at a more detailed and quantitative level, and thereby improve predictability of efficacy and therapeutic utility of drug candidates in clinical trials”.

In Vitro Services

QPS Austria’s Neuropharmacology Department provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.

In Vivo Services

We have more than 15 years experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects. Several customized behavioral tests, including motor, cognitive, and emotional assays, are offered to phenotype mouse and rat models and to evaluate effects of compounds in different in vivo models.

Ex Vivo Services

Our ex vivo services cover a full range of histological services, a biobank composed of various specimen derived from our in-house in vivo and in vitro models, and numerous well established tests for biomarkers. We are happy to test new protocols and establish new markers to meet your specific needs.